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Abstract: This study aimed to assess the protective potential of glimepiride and Nerium oleander extract on lipid profile, body
growth rate, and renal function in streptozotocin-induced diabetic rats. The animals were divided into control and experimental
groups. The experimental group was rendered diabetic by intraperitoneal injection of a single dose of 50 mg/kg body weight
streptozotocin. Rats with glucose levels >200 mg/dl were subdivided into 3 sub-groups. Rats in the first sub-group remained
without treatment and were considered diabetic. Those in the second and third subgroups were orally administered 0.1 mg/kg body
weight daily glimepiride and 250 mg/kg body weight daily Nerium oleander extract, respectively, for 4 weeks. In the streptozotocininduced diabetic rats, serum triglycerides and cholesterol were significantly increased whereas body growth rate was markedly
decreased compared to the controls. In contrast to uric acid and creatinine, urea concentrations were markedly elevated. Treatment
of diabetic rats with glimepiride or plant extract improved all of these parameters, indicating their antidiabetic efficacy.
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Introduction
Diabetes is a major threat to global public health that
is rapidly getting worse, and the biggest impact is on
adults of working age in developing countries. At least
171 million people worldwide have diabetes. This figure
is likely to be more than double by 2030 to reach 366
million (1). Insufficient production of insulin (either
absolutely or relative to the body's needs), or the inability
of cells to use insulin properly and efficiently leads to
hyperglycemia and diabetes (2). The effect of diabetes is
not limited to carbohydrate metabolism. Lipid and protein
metabolism play an important role in the progression of
the disease (3).
Induction of diabetes in laboratory animals is a
convenient and useful strategy in the understanding and
treatment of the disease. An appropriate dose of
streptozotocin was used to induce experimental diabetes.
Streptozotocin selectively destroyed pancreatic β cells,
resulting in hypoinsulinemia (4).
In diabetes there is inability to store fat and protein
along with breakdown of existing fat and protein stores.

Streptozotocin-induced diabetic rats showed significant
increases in the levels of cholesterol, phospholipids,
triglycerides, and free fatty acids (5,6). These changes
remain important in terms of explaining the accelerated
atherosclerosis. In addition, there is a loss of body weight
(7).
Impairment of kidney function is a prominent feature
of diabetes. Elevated levels of urea and decreased
concentrations of uric acid and creatinine were shown in
diabetes (8,9). Over time diabetic nephropathy will
develop, characterized by proteinuria, a loss of renal
function, and a rapid progression to end-stage renal
failure (10).
Glimepiride is a novel sulfonylurea used as the drug
of choice in the treatment of type II diabetes in the Gaza
Strip. The hypoglycemic activity of glimepiride relied on
its ability to enhance insulin release and action (11,12).
Although some studies have assessed Nerium oleander
toxicity and its cure action in diluted preparations
(13,14), to the best of our knowledge no research has
been conducted on it as an anti-diabetic plant.
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The present research was carried out to assess the
protective potential of the synthetic sulfonylurea drug
glimepiride and Nerium oleander plant extract on lipid
profile, body growth rate, and renal function in
streptozotocin-induced diabetic rats. The findings could
translate into better protection against human diabetes.

Materials and Methods
Experimental animals
Male Sprague-Dawley rats weighing 170 ± 30 g were
used throughout the study. The animals were maintained
under ambient conditions in the animal house in the
Department of Biology, The Islamic University of Gaza.
They were fed a commercial balanced diet and water was
provided with fresh supply daily throughout the
experimental period.
Induction of diabetes and treatment
The animals were divided into 2 major groups: control
and experimental groups. The experimental group of
animals was fasted for 24 h and then intraperitoneally
injected with a single dose of 50 mg/kg body weight of
freshly prepared streptozotocin dissolved in citrate buffer
pH 4.5. Streptozotocin was purchased from Himedia
Laboratory Limited, Mumbai, India. The dose of
streptozotocin was based on previous work (4,15). Rats
with glucose levels >200 mg/dl were subdivided into 3
subgroups. Those in the first subgroup remained without
treatment and were considered diabetic. Those in the
second subgroup were given glimepiride and considered
the glimepiride-treated subgroup. Glimepiride was
purchased from local pharmacies in tablet form and
ground using a mortar. The powder was dissolved in
distilled water and orally administered at a dose of 0.1
mg/kg body weight per day for the experimental period
of 4 weeks. The dose of glimepiride was based on
previous studies (12,16). The third subgroup received
Nerium oleander plant extract and was considered the
Nerium oleander extract-treated subgroup. This plant
belongs to the family apocynaceae. Leaves were collected
from plants growing in the Gaza strip from different
localities on road sides and gardens during May and June,
2005. The leaves were washed with water and dried
under shade, then smashed by hand in a small pore sieve
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and stored in a dark dry place at room temperature. Leaf
extract was obtained using aqueous decoction (17). The
extract was orally administered at a dose level of 250
mg/kg body weight per day for 4 weeks. The dose of
Nerium oleander extract was based on previous
toxicological studies (14,18). Oral administration of
glimepiride and Nerium oleander extract was done using
a special stomach tube with a smooth tip to protect the
interior lining of the oral and buccal cavity of the animal
from injury.
Monitoring of body growth rate
Animals were individually weighed daily in order to
record the changes in their body growth rates. A sensitive
balance was used.
Blood sampling and processing
At each sampling date, 8 rats were taken from the
control group and 6 rats from each subgroup per week.
The animals were decapitated and blood samples were
then collected into centrifuge tubes. The collected blood
was allowed to clot. Clear serum samples were obtained
by centrifugation at 3000 rpm for 20 min and then kept
in the refrigerator for bioassay.
Determination of triglyceride and cholesterol
Serum triglyceride levels were measured by
colorimetric enzymatic test using glycerol-3-phosphateoxidase (19) with DiaSys reagent kits. Serum cholesterol
was determined with a "CHOD-PAP" enzymatic
photometric test (20) using DiaSys reagent kits.
Determination of urea, uric acid, and creatinine
Serum urea was determined by colorimetric test (21)
using DiaSys reagent kits. Serum uric acid was measured
by direct enzymatic assay (22) using DiaSys reagent kits.
Serum creatinine was determined by kinetic test without
deproteinization (23) using DiaSys reagent kits.
Data analysis
The data were analyzed using SPSS version 11.0 for
Windows (Statistical Package for the Social Sciences Inc,
Chicago, IL, USA). Means were compared by independentsamples t-test. A probability level less than 0.05 was
regarded as significant. Percentage changes were also
calculated.
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Serum urea, uric acid and creatinine

Results
Serum triglyceride and cholesterol
Streptozotocin-induced diabetic rats showed
significant increases in the levels of serum triglyceride and
cholesterol, registering increases of 27.3% and 25.6%,
respectively, at the end of the experiment compared to
the controls. Glimepiride and Nerium oleander extract
treatment lowered serum triglyceride in diabetic rats to
increases of 10.1% and 14.5%, respectively. This
protective effect was also observed for cholesterol, where
increases in diabetic rats treated with glimepiride and
Nerium oleander extract were 9.3% and 15.9%,
respectively (Tables 1 and 2).
Body growth rate
Table 3 shows a marked decrease in the body growth
rate of diabetic rats throughout the experimental period,
with a decrease of 64.7% at the end of the experiment
compared to the controls. Treatment of diabetic animals
with glimepiride and Nerium oleander extract improved
the growth rate, recording decreases of 28.4% and
37.5%, respectively, compared to the controls.

Streptozotocin-induced diabetic animals showed a
significant elevation in serum urea concentrations, with
an increase of 33.0% at the end of the experiment
compared to the controls. Glimepiride therapy returned
urea concentrations to near control values, showing an
increase of 10.5%. On the other hand, urea
concentrations still showed a significant increase, with
Nerium oleander extract treatment recording an increase
of 17.1% compared to the controls (Table 4). In
contrast, serum uric acid and creatinine exhibited
significant decreases in streptozotocin-induced diabetic
rats, with percentages of 17.5% and 23.7%,
respectively, at the end of the experiment compared to
the controls. Both glimepiride and Nerium oleander
extract treatment reversed such changes to approach
control levels (Tables 5 and 6).

Discussion and Conclusion
The current study is the second part of our work on
diabetes. In the first part most of the rats in our

Table 1. Serum triglyceride level (mg/dl) in control, streptozotocin-diabetic, glimepiride and Nerium oleander extracttreated albino rats at different time intervals.
Experimental Period (Week)
Treatment
1

2

3

4

Control

65.4 ± 3.1

59.8 ± 3.2

66.7 ± 2.7

68.2 ± 3.0

Diabetic

73.1 ± 3.7

70.3 ± 2.8

83.4 ± 3.3

86.8 ± 3.6

% Change
P
Glimepiride-treated diabetics
% Change
P
Nerium oleander- treated diabetics
% Change
P

11.8

17.6

25.0

27.3

>0.05

<0.05

<0.01

<0.01

68.6 ± 3.8

63.4 ± 3.0

69.8 ± 2.6

75.1 ± 3.1

4.9

6.0

4.6

10.1

>0.05

>0.05

>0.05

>0.05

70.8 ± 2.9

66.0 ± 3.4

75.5 ± 2.9

78.1 ± 3.1

8.3

10.4

13.2

14.5

>0.05

>0.05

<0.05

<0.05

The number of animals was 6 in each experimental interval for each treatment except for the control, in which it was 8.
All values are expressed as means ± S.E.M.
P > 0.05: non-significant, P < 0.05: significant, P < 0.01: highly significant, P < 0.001: more highly significant.
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Table 2. Serum cholesterol level (mg/dl) in control, streptozotocin-diabetic, glimepiride and Nerium oleander extracttreated albino rats at different time intervals.
Experimental Period (Week)
Treatment
1

2

3

4

Control

80.3 ± 3.2

82.1 ± 2.8

83.8 ± 2.9

78.6 ± 3.1

Diabetic

88.4 ± 2.9

93.8 ± 3.1

101.5 ± 3.2

98.7 ± 3.0

10.1

14.3

21.1

25.6

>0.05

<0.05

<0.01

<0.01

84.9 ± 29

86.4 ± 3.4

89.5 ± 3.5

85.9 ± 3.2

% Change
P
Glimepiride-treated diabetics
% Change
P
Nerium oleander- treated diabetics
% Change
P

5.7

5.2

6.8

9.3

>0.05

>0.05

>0.05

>0.05

86.3 ± 3.1

89.6 ± 3.5

94.5 ± 3.5

91.1 ± 3.3

7.5

9.1

12.8

15.9

>0.05

>0.05

<0.05

<0.05

The number of animals was 6 in each experimental interval for each treatment except for the control, in which it was 8.
All values are expressed as means ± S.E.M.
P > 0.05: non-significant, P < 0.05: significant, P < 0.01: highly significant, P < 0.001: more highly significant.

Table 3. Body growth rate (g/day) in control, streptozotocin-diabetic, glimepiride and Nerium oleander extract-treated
albino rats at different time intervals.
Experimental Period (Week)
Treatment
1

2

3

4

Control

4.37 ± 0.26

4.77 ± 0.21

4.28 ± 0.21

3.63 ± 0.20

Diabetic

2.10 ± 0.22

1.33 ± 0.25

1.27 ± 0.30

1.28 ± 0.21

% Change
P
Glimepiride-treated diabetics

-51.9

-72.1

-70.3

-64.7

<0.001

<0.001

<0.001

<0.001

3.92 ± 0.29

3.08 ± 0.29

2.95 ± 0.28

2.60 ± 0.17

% Change

-10.3

-35.4

-31.1

-28.4

P

>0.05

<0.01

<0.01

<0.01

3.55 ± 0.25

2.35 ± 0.19

2.38 ± 0.31

2.27 ± 0.16

Nerium oleander- treated diabetics
% Change

-18.8

-50.7

-44.4

-37.5

P

<0.05

<0.001

<0.001

<0.001

The number of animals was 6 in each experimental interval for each treatment except for the control, in which it was 8.
All values are expressed as means ± S.E.M.
P > 0.05: non-significant, P < 0.05: significant, P < 0.01: highly significant, P < 0.001: more highly significant.
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Table 4. Serum urea concentrations (mg/dl) in control, streptozotocin-diabetic, glimepiride and Nerium oleander extracttreated albino rats at different time intervals.
Experimental Period (Week)
Treatment
1

2

3

4

Control

33.6 ± 1.6

37.4 ± 1.9

34.8 ± 1.8

35.1 ± 1.7

Diabetic

41.5 ± 2.2

51.8 ± 2.7

47.1 ± 2.5

46.7 ± 2.1

23.5

38.5

35.3

33.0

<0.05

<0.01

<0.01

<0.01

36.7 ± 2.0

42.5 ± 2.0

39.2 ± 2.3

38.8 ± 2.1

% Change
P
Glimepiride-treated diabetics
% Change
P
Nerium oleander- treated diabetics
% Change
P

9.2

13.6

12.6

10.5

>0.05

>0.05

>0.05

>0.05

37.8 ± 2.3

45.6 ± 2.1

42.3 ± 2.0

41.1 ± 1.9

12.5

21.9

21.6

17.1

>0.05

<0.05

<0.05

<0.05

The number of animals was 6 in each experimental interval for each treatment except for the control, in which it was 8.
All values are expressed as means ± S.E.M.
P > 0.05: non-significant, P < 0.05: significant, P < 0.01: highly significant, P < 0.001: more highly significant.

Table 5. Serum uric acid concentrations (mg/dl) in control, streptozotocin-diabetic, glimepiride and Nerium oleander
extract-treated albino rats at different time intervals.
Experimental Period (Week)
Treatment
1

2

3

4

Control

1.72 ± 0.08

1.76 ± 0.07

1.69 ± 0.06

1.77 ± 0.08

Diabetic

1.65 ± 0.10

1.57 ± 0.09

1.44 ± 0.08

1.46 ± 010

% Change
P
Glimepiride-treated diabetics
% Change
P
Nerium oleander- treated diabetics
% Change
P

-4.1

-10.8

-14.8

-17.5

>0.05

>0.05

<0.05

<0.05

1.69 ± 0.09

1.78 ± 0.11

1.61 ± 0.09

1.66 ± 0.10

-1.7

-1.1

-4.7

-6.2

>0.05

>0.05

>0.05

>0.05

1.64 ± 0.08

1.68 ± 0.1

1.57 ± 0.1

1.59 ± 0.11

-4.7

-4.5

-7.1

-10.2

>0.05

>0.05

>0.05

>0.05

The number of animals was 6 in each experimental interval for each treatment except for the control, in which it was 8.
All values are expressed as means ± S.E.M.
P > 0.05: non-significant, P < 0.05: significant, P < 0.01: highly significant, P < 0.001: more highly significant.
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Table 6. Serum creatinine concentrations of (mg/dl) in control, streptozotocin-diabetic, glimepiride and Nerium oleander
extract-treated albino rats at different time intervals.
Experimental Period (Week)
Treatment
1

2

3

4

Control

0.62 ± 0.02

0.58 ± 0.03

0.61 ± 0.02

0.59 ± 0.02

Diabetic

0.60 ± 0.03

0.50 ± 0.02

0.48 ± 0.02

0.45 ± 0.03

-3.2

-13.8

-21.3

-23.7

>0.05

<0.05

<0.01

<0.01

0.63 ± 0.04

0.56 ± 0.03

0.56 ± 0.04

0.55 ± 0.03

% Change
P
Glimepiride-treated diabetics
% Change
P
Nerium oleander- treated diabetics
% Change
P

-1.6

-3.4

-8.2

-6.8

>0.05

>0.05

>0.05

>0.05

0.61 ± 0.04

0.55 ± 0.03

0.54 ± 0.03

0.52 ± 0.04

-1.6

-5.2

-11.5

-11.9

>0.05

>0.05

>0.05

>0.05

The number of animals was 6 in each experimental interval for each treatment except for the control, in which it was 8.
All values are expressed as means ± S.E.M.
P > 0.05: non-significant, P < 0.05: significant, P < 0.01: highly significant, P < 0.001: more highly significant.

laboratory developed hypoinsulinemia and hyperglycemia
following streptozotocin injection. This persisted
throughout the whole experimental duration of 4 weeks,
where a strong negative correlation (r = -0.8) was
obtained between insulin and glucose levels (24).
Increased levels of serum triglycerides and cholesterol
observed in streptozotocin-induced diabetic rats were in
accord with other studies (25,26). The abnormal high
concentrations of serum lipids in diabetic animals are due
mainly to an increase in the mobilization of free fatty
acids from the peripheral fat depots, since insulin inhibits
the hormone-sensitive lipase (27). Excess fatty acids in
the serum of diabetic rats are converted into
phospholipids and cholesterol in the liver. These 2
substances along with excess triglycerides formed at the
same time in the liver may be discharged into the blood
in the form of lipoproteins (28). The antilipidemic action
of glimepiride and Nerium oleander extract may reside in
their ability to stimulate insulin secretion and action
(12,24).
Diabetic rats exhibited decreases in body growth rate.
The reduction in body weight may be attributed to insulin
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depletion provoking a loss of adipose tissues and due to
changes in carbohydrates and protein metabolism that
occur in rats with streptozotocin-induced diabetes (29).
Such a finding is in agreement with previous studies
(30,31). However, treatment of diabetic rats with
glimepiride or Nerium oleander extract did improve body
growth rate. This may be explained by enhancement of
insulin secretion and action (12,24). It was demonstrated
that glimepiride is associated with weight neutrality in
diabetics (32).
The data revealed significant elevations in serum urea
in streptozotocin-induced diabetic rats. A similar effect
was recorded previously (8). Enhanced protein
catabolism and accelerated amino acid deamination for
gluconeogenesis is probably an acceptable postulate to
interpret the elevated levels of urea. In contrast, serum
uric acid and creatinine were decreased in diabetic
animals. Possible defects in tubular reabsorption and
probably increased excretion may explain such decreases
in serum uric acid and creatinine. Creatinuria occurs in
any condition associated with extensive muscle
breakdown as in starvation and poorly controlled diabetes
mellitus (33). However, uric acid clearance has been
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associated with insulin resistance (34). Previous changes
in serum urea, uric acid, and creatinine concentrations
strongly suggested impairment of kidney function in
diabetes.

creatinine were decreased. Treatment of diabetic rats
with glimepiride and Nerium oleander extract offered
protection in terms of lipid profile, growth rate and renal
function, indicating their antidiabetic potential.

Glimepiride and Nerium oleander extract therapy
returned such changes in urea, uric acid, and creatinine
towards normal. The main effect of the sulfonylureas and
possibly the plant extract is enhancement of insulin
secretion and improvement of metabolism both by
pancreatic and extrapancreatic mechanisms (24,35).
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